Report from the extraordinary general meeting of Genovis AB (publ)

At the extra general meeting of Genovis AB (publ) held on 28 March 2011, was approved the board’s proposed new share issue and authorization for the board to decide upon a new share issue, up until May 30, 2011 at one or more occasions.

The share capital in the company will increase by up to SEK 12 336 562.8 through a new share issue of up to 30 841 407 shares with preference for existing shareholders. Four (4) existing shares, will qualify for subscription of three (3) new shares at the issue price SEK 0.65.

Following the completed share issue, share capital will amount to a maximum of SEK 28,785,313.6 and the number of shares to 71,963,284. If the oversubscription option is exercised the share capital will amount to a maximum of SEK 33,985,313.6 and the number of shares to 84,963,284.

Timetable for the issue 2011

April 4 - Last trading day for the Genovis share that includes the right to participate in the new share issue.

April 7 - Record day for participation in the new share issue, i.e., shareholders listed in the Genovis share register on this day receive subscription rights for participation in the new share issue.

April 13 – May 6 - Subscription period. Subscription with preemptive rights occurs through cash payment during the subscription period. Notification of interest in subscribing can be done during the entire subscription period.

April 13 – May 3 - Rights trading.

For more information, please contact: Sarah Fredriksson, CEO, Genovis AB Tel: 46 46 10 12 35 sarah.fredriksson@genovis.com

Genovis develops and designs smart nanoparticles for preclinical imaging and diagnostics and also develops and sells tools for modification of antibodies.Genovis shares are listed on Nasdaq OMX First North and Thenberg & Kinde Fondkommission ( 46 (0)31 745 50 00) is the Company’s certified adviser.